BioVie Receives FDA Fast Track Designation for BIV201 for the Treatment of Refractory Ascites Due to Advanced Liver Cirrhosis

Dec 11, 2017

BEVERLY, MA--(Marketwired - December 11, 2017) - BioVie Inc. (OTCQB: BIVI), a clinical-stage company focused on the development and commercialization of innovative drug therapies for liver disease, announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation for...

BioVie Announces Second Patient Dosed with BIV201 in Phase 2a Clinical Trial; First Patient Completes 28-day Treatment Regimen

Nov 8, 2017

BEVERLY, MA--(Marketwired - November 08, 2017) - BioVie Inc. (OTCQB: BIVI), a clinical-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, reported today that a second patient has been dosed with the Orphan drug candidate BIV201 ...

Accomplished BioPharma Executive Mina Sooch Joins BioVie Board of Directors and Purchases Company Stock

Nov 2, 2017

BEVERLY, MA--(Marketwired - November 02, 2017) - BioVie Inc. (OTCQB: BIVI), a clinical-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, today welcomed Mina Sooch, a highly seasoned biopharma industry executive, to its Board o...